Flunixin meglumine is a relatively potent non-narcotic, non-steroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties.

In the horse, Flunixin Injection is indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders and for the alleviation of visceral pain associated wit colic. In cattle, Flunixin Injection is indicated for the control of acute inflammation associated with respiratory disease. Flunixin Injection has also been shown to have some benefit in the treatment of acute pulmonary emphysema (fog fever). It may also be used as adjunctive therapy in the treatment of acute mastitis.

Horses- For use in equine colic, the recommended dose rate is 1.1mg flunixin/kg bodyweight equivalent to 1ml per 45kg bodyweight by intravenous injection. Treatment may be repeated once or twice if colic recurs. For use in musculo-skeletal disorders, the recommended dose rate is 1.1mg flunixin/kg bodyweight, equivalent to 1ml per 45kg bodyweight, injected intravenously once daily for up to 5 days according to clinical response. For the treatment of endotoxaemia or septic shock associated with gastric torsion and other conditions in which the gastrointestinal tract is comprised: 0.25mg/kg (1ml per 200kg) every 6-8 hours.

Cattle- The recommended dose rate is 2.2mg flunixin / kg bodyweight equivalent to 2ml per 45kg bodyweight injected intravenously and repeated as necessary at 24 hour intervals for up to 5 consecutive days.

• ·    Do not exceed the recommended dose or the duration of treatment.

• ·    Do not administer to pregnant mares.

• ·    Monitor drug compatibility closely where adjunctive therapy is required.

• ·    Avoid intra-arterial injection.

• ·    It is preferable that NSAIDs, which inhibit prostaglandin synthesis, are not administered to animals undergoing general anaesthesia until fully recovered.

• ·    Horses intended for racing and competition should be treated according to local requirements and appropriate precautions must be taken to ensure compliance with the competition regulations. In case of doubt it is advisable to test the urine.

• ·    The cause of the underlying inflammatory condition or colic should be determined and   treated with apropriate concomitant therapy.

• ·    Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro9intestinal ulceration or bleeding, where there is evidence of a blood dyscrasia or hypersensitivity to the product.

•   ·  Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs) concurrently or  

•      within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and 

•      compete with other highly bound drugs which can leas to toxic effects.

• ·    Use in any animal less than 6 weeks of age or in aged animals may involve an additional risk. If such use can not be avoided animals may require may require a reduced dosage and careful clinical management.

• ·    Avoid use in any dehydrated, hypovolaemic or hypotensive animal, except in the case of endotoxaemia or septic shock, as there is a potential risk of increased renal toxicity.

• ·    Concurrent administration of potentially nephrotoxic drugs should be avoided.

Animals must not be slaughtered for human consumption during treatment.

Cattle may be slaughtered for human consumption only after14 days form the last treatment. Horses may be slaughtered for human consumption only after 28 days from the last treatment.

Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken form treated cows after2 days from the last treatment.